Original source text
LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a Live financial news intelligence
Track market-moving stories before they get noisy
Real-time pulse of financial headlines curated from 5 premium feeds.
Commodities
GOLD
181
SILVER
103
OIL
60
PLATINUM
5
PALLADIUM
2
COPPER
1
- FMP Stock News 40s ago
- FMP Forex News 40s ago
- CoinGecko News 40s ago
- FIO Stock News 9m ago
- Patria Stock News 9m ago
- Editorial rewrite 40s ago
- Asset sync 29m ago
Latest coverage
Market News Feed
Scan headlines quickly, then expand any story for source context.
| Details | Date | Content | Source |
|---|---|---|---|
|
Saved
2026-07-14 17:34
14d ago
Published
2026-07-14 12:00
14d ago
|
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat | FMP Stock News | |
|
|
|||
|
Saved
2026-07-14 17:34
14d ago
Published
2026-07-14 12:00
14d ago
|
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 | FMP Stock News | |
|
Original source text
More than 75% of LeqembiÂ-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEAD |
|||
|
Saved
2026-06-24 15:36
1mo ago
Published
2026-06-24 09:00
1mo ago
|
Applied Biomics Launches New Antigen Affinity Purified HCP Antibody with 95% Coverage | FMP Stock News | |
|
Original source text
HAYWARD, Calif.--(BUSINESS WIRE)--Applied Biomics, Inc., a leading provider of Host Cell Protein (HCP) products and HCP services, today announced the new Antigen Affinity Purified HCP Antibodies. The new product line expands the company's portfolio of high-performance HCP antibody solutions for use in biopharmaceutical process development and quality control.95% HCP Coverage — Significantly Higher Than Leading Commercial Alternatives Share Unlike conventional antigen affinity-purified antibodies, which often recognize only a limited subset of HCPs, Applied Biomics' Antigen Affinity Purified CHO HCP Antibody was specifically developed to maximize HCP coverage, an essential characteristic for capture antibodies used in HCP ELISA assays. The antibody is affinity purified from Applied Biomics' goat anti-CHO HCP polyclonal antibody, which demonstrates greater than 99% HCP coverage. In an internal 2D Western blot evaluation against CHO HCPs, the Antigen Affinity Purified CHO HCP Antibody achieved 95% HCP coverage, compared with 66% coverage using a leading commercially available antigen affinity-purified CHO HCP antibody. Key Features 95% overall HCP coverage Compatible with: ELISA (capture and detection antibody) 1D Western Blot 2D Western Blot Immunoprecipitation (IP) for immunocapture LC-MS (IAC-MS) Broad reactivity with major CHO production cell lines, including CHO-S, CHO-K1, CHO-GS and CHO-DG44 Complements Applied Biomics' existing Serum and IgG CHO HCP antibody product portfolio Competitive pricing The new Antigen Affinity Purified HCP Antibody further strengthens the company's integrated HCP solution portfolio: HCP antibodies: Serum, IgG and Antigen Affinity Purified HCP Antigens HCP antibody coverage services Custom HCP antibody development HCP profiling services, and LC-MS/MS based HCP characterization About Applied Biomics Applied Biomics, Inc. is a leading provider of HCP products and analytical services. Since 2005, the company has supported biotechnology, pharmaceutical, and academic organizations worldwide with comprehensive HCP solutions, including HCP antibodies and reagents, HCP antibody coverage analysis via proprietary 2D Fluorescent Western Blot and HCP profiling services. Headquartered in the San Francisco Bay Area, Applied Biomics also offers a full suite of proteomics services, including LC-MS/MS, quantitative proteomics and protein characterization, helping accelerate biopharmaceutical process development, biomarker discovery and proteomics researches. Contact Applied Biomics to discover HCP products tailored to your needs and discuss your HCP-related projects. More News From Applied Biomics, Inc. |
|||
|
Saved
2026-06-12 15:37
1mo ago
Published
2026-03-18 15:29
4mo ago
|
Vercel Appoints Mitchell Hashimoto, Co-Founder of HashiCorp and Creator of Terraform, to Board of Directors | FMP Stock News | |
|
Original source text
Open source pioneer and serial founder brings deep developer community roots and infrastructure expertise to Vercel’s boardSAN FRANCISCO--(BUSINESS WIRE)--Vercel, the agentic infrastructure company, today announced the appointment of Mitchell Hashimoto, co-founder of HashiCorp and creator of industry-defining open source tools including Terraform and Vagrant, to its board of directors. Hashimoto brings a rare combination of developer community credibility, open source leadership, and company-building experience at scale. “Vercel checks every box for what I care most about: a powerful developer presence, industry-defining products, and a team building for our agentic future." Share Hashimoto co-founded HashiCorp in 2012, where he served as a principal architect and engineering leader behind some of the most widely adopted infrastructure tools in the world. Terraform, which he created, has become the de facto standard for infrastructure-as-code and is used by organizations of every scale, including Vercel itself. IBM acquired HashiCorp in 2024 in a transaction valued at approximately $6.4 billion. After departing HashiCorp, Hashimoto launched Ghostty, a GPU-accelerated, platform-native terminal emulator that quickly became a market leader among AI developers since its public release in December 2024. “Mitchell is inimitable as an advisor: he’s built tools that nearly every developer uses, grown a company to a multi-billion dollar outcome, and then stepped back into the arena as a builder,” said Guillermo Rauch, founder and CEO of Vercel. “He has been a Vercel customer and Next.js user since our earliest days. There aren’t many people who understand our mission more, and we’re honored to have him on the board.” Hashimoto also cited his long personal history with Vercel’s products as a key reason for joining the board. He joins at a moment of significant momentum for Vercel, following its $300 million Series F fundraise at a $9.3 billion valuation, and as reflected in the company’s $340M GAAP Revenue run-rate and 84% YoY growth. “Vercel checks every box for what I care most about: a powerful developer presence, industry-defining products, and a team building for our agentic future,” said Hashimoto. “I’ve watched Vercel grow from the perspective of a founder, an engineer, and a customer, and I’m excited to help in every way I can as they build the agentic infrastructure for frontends, backends, and agents.” Hashimoto is one of the most recognized figures in the open source community, consistently ranked among the most active contributors on GitHub globally over more than a decade. His work has shaped how developers build, deploy, and operate software at every layer of the stack. He has also been a committed advocate for open source sustainability, making significant philanthropic contributions to projects including the Zig programming language. “Mitchell understands something that is easy to say but hard to actually do: winning developers means earning their trust over many years through great software,” said Tom Occhino, Chief Product Officer at Vercel. “He built the tools that helped define modern infrastructure by making them genuinely excellent, not by locking anyone in. That philosophy is deeply aligned with how we think about Vercel’s role in the ecosystem.” Hashimoto joins a distinguished group of board members and advisors supporting Vercel’s mission to enable the world to build with the speed, security, and scalability required to win with AI, including Stripe CFO Steffan Tomlinson and Susan St. Ledger, former President of Worldwide Field Operations at HashiCorp. About Vercel Vercel is the agentic infrastructure for every app and agent. As the team behind AI SDK, Next.js, and v0, Vercel is the platform where humans and agents build and deploy software, while infrastructure improves it autonomously. To ship for the AI-native web, visit vercel.com |
|||
|
Saved
2026-06-12 15:37
1mo ago
Published
2026-06-04 09:00
1mo ago
|
Critical Infrastructure Technologies Provides an Update to its Executed Letter of Intent with H. Cegielski - Poznan S.A. | FMP Stock News | |
|
Original source text
Vancouver, BC – TheNewswire - June 4, 2026 – Critical Infrastructure Technologies Ltd. (CSE: CTTT) (OTC: CITLF) (FRA: X9V) (“CiTech” or the “Company”), a leading developer of autonomous, high-capacity mobile communications and security platforms, is pleased to provide an update to its executed Letter of Intent (LOI) with H. Cegielski – Poznań S.A. (HCP), a subsidiary of Polska Grupa Zbrojeniowa S.A. (PGZ), one of Poland's leading defence and industrial groups. HCP, headquartered in Poznań, is a historic and strategically significant manufacturing enterprise within the Polish defence sector, to establish a long-term strategic partnership focused on the production and deployment of the Nexus 20 autonomous platform in Central and eastern Europe. The LOI reflects a shared intent to combine CiTech's Nexus 20 technology with HCP's established manufacturing, integration, and support capabilities to address the requirements of the Polish Armed Forces and NATO's Eastern Flank. |
|||